Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 12/20 | 0.48 |
| ▸ | CHRNB4 | P30926 | 12/20 | 0.48 |
| ▸ | CHRNA3 | P32297 | 12/20 | 0.48 |
| ▸ | CHRNA4 | P43681 | 12/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.47 |
| ▸ | HCRTR2 | O43614 | 7/20 | 0.46 |
| ▸ | HCRTR1 | O43613 | 6/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1672249 | 0.83 | HCRTR2 (0.50) | CHRNB2CHRNA4HCRTR2HCRTR1 | |
| SCHEMBL26046517 | 0.82 | HCRTR2 (0.52) | HCRTR2HCRTR1 | |
| SCHEMBL1586761 | 0.81 | ROCK2 (0.56) | CHRNB2CHRNB4CHRNA3CHRNA4ROCK2 | |
| SCHEMBL30556702 | 0.81 | HCRTR2 (0.51) | HCRTR2HCRTR1 | |
| SCHEMBL30615962 | 0.81 | HCRTR2 (0.51) | HCRTR2HCRTR1 | |
| SCHEMBL30556681 | 0.78 | HCRTR2 (0.49) | HCRTR2HCRTR1 | |
| SCHEMBL26046519 | 0.78 | HCRTR2 (0.52) | HCRTR2HCRTR1 | |
| SCHEMBL1586792 | 0.78 | HCRTR1 (0.55) | HCRTR2HCRTR1 | |
| SCHEMBL20064225 | 0.74 | HCRTR2 (0.45) | HCRTR2HCRTR1 | |
| SCHEMBL26201767 | 0.74 | KDM4E (0.46) | HCRTR2HCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023163712-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | NALO THERAPEUTICS (US) | 2023-08-31 | — | — | WO | disclosed |
| US-9062044-B2 | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2015-06-23 | — | — | US | disclosed |
| US-9062044-B2 | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2015-06-23 | — | — | US | disclosed |
| US-9062044-B2 | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2015-06-23 | — | — | US | disclosed |
| EP-2491031-B1 | FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2013-08-07 | — | — | EP | disclosed |
| US-20130137672-A1 | DISUBSTITUTED OCTAHYDROPYRROLO[3,4-c]PYRROLES AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2013-05-30 | — | — | US | disclosed |
| US-20130137672-A1 | DISUBSTITUTED OCTAHYDROPYRROLO[3,4-c]PYRROLES AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2013-05-30 | — | — | US | disclosed |
| US-20130137672-A1 | DISUBSTITUTED OCTAHYDROPYRROLO[3,4-c]PYRROLES AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2013-05-30 | — | — | US | disclosed |
| EP-2491031-A1 | FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS | Janssen Pharmaceutica N.V. (BE) | 2012-08-29 | — | — | EP | disclosed |
| WO-2011050202-A1 | FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137672-A1 | DISUBSTITUTED OCTAHYDROPYRROLO[3,4-c]PYRROLES AS OREXIN RECEPTOR MODULATORS | HCRTR2, HCRTR1, OXTR | CHRNB2 479/4885CHRNB4 537/4885CHRNA3 299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.